RPTX Company Profile and Key Details

Q: Who are the executives of RPTX?

Dr. Frank Sicheri Ph.D.Co-FounderDr. Daniel Durocher Ph.D.Co-FounderDr. Michael Zinda Ph.D.Executive Vice President & Chief Scientific OfficerMr. Cameron BlackExecutive Vice President of DiscoveryMr. Philip HermanExecutive Vice President, Chief Commercial & Portfolio Devel. OfficerDr. Kim A. Seth Ph.D.Executive Vice President & Chief Bus. OfficerMr. Steve ForteExecutive Vice President & Chief Financial OfficerDr. Agnel Sfeir Ph.D.Co-FounderMr. Daniel BelangerExecutive Vice President of Human ResourceDr. Maria Koehler M.D., Ph.D.Executive Vice President & Chief Medical OfficerMr. Lloyd Mitchell SegalPres, Chief Executive Officer & Director

NASDAQ : RPTX

Repare Therapeutics

$2.65

At Close 4:00 PM

Not Actively Trading

62.32

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Repare Therapeutics Inc. (RPTX) stock remained unchanged at $2.65 a share on NASDAQ. The stock opened at $2.65, fluctuating between $2.65 to $2.65 during the session.

Stock Snapshot

2.65

Prev. Close

114.24M

Market Cap

2.65

Day Low

-1.5588235294117647

P/E Ratio

-1.7

EPS (TTM)

-3.06

Cash Flow per Share

2.65

Open

43.11M

Number of Shares

2.65

Day High

71.75%

Free Float in %

5.03

Book Value

1.17M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 27, 2026	2.64	2.65	2.62	2.65	1.18M
Jan 26, 2026	2.62	2.64	2.61	2.63	448.68K
Jan 23, 2026	2.60	2.63	2.59	2.62	290.05K
Jan 22, 2026	2.59	2.60	2.57	2.59	997.2K
Jan 21, 2026	2.56	2.60	2.56	2.59	935.33K
Jan 20, 2026	2.57	2.60	2.50	2.58	4.16M
Jan 16, 2026	2.57	2.59	2.56	2.58	525.74K
Jan 15, 2026	2.59	2.60	2.56	2.57	499.54K
Jan 14, 2026	2.59	2.61	2.58	2.60	426.04K
Jan 13, 2026	2.56	2.59	2.55	2.59	469.29K
Jan 12, 2026	2.56	2.58	2.54	2.57	560.35K
Jan 09, 2026	2.56	2.57	2.53	2.54	836.17K
Jan 08, 2026	2.56	2.56	2.52	2.53	3.1M
Jan 07, 2026	2.57	2.57	2.55	2.56	970.31K
Jan 06, 2026	2.57	2.58	2.55	2.57	1.43M
Jan 05, 2026	2.59	2.59	2.56	2.57	666.03K
Jan 02, 2026	2.62	2.63	2.56	2.57	920.8K
Dec 31, 2025	2.61	2.66	2.60	2.60	472.77K
Dec 30, 2025	2.56	2.61	2.56	2.58	826.98K
Dec 29, 2025	2.59	2.60	2.56	2.56	613.95K

Contact Details

Montreal, QC H4S 2A1

Canada

https://www.reparerx.com 857 412 7018

About Company

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Stock Peers

ARGX

-5.14-0.65%

argenx SE$782.17 REGN

5.79+0.82%

Regeneron Pharmaceuticals, Inc.$714.89 UTHR

-4.24-0.74%

United Therapeutics Corporation$564.94 MDGL

-24.82-4.64%

Madrigal Pharmaceuticals, Inc.$510.04 VRTX

4.82+1.13%

Vertex Pharmaceuticals Incorporated$429.82 PRAX

-3.26-0.98%

Praxis Precision Medicines, Inc.$330.02 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

9.01+3.04%

Krystal Biotech, Inc.$305.71 ALNY

-0.86-0.29%

Alnylam Pharmaceuticals, Inc.$295.05 ASND

-7.48-3.04%

Ascendis Pharma A/S$238.66

Company Overview

The stock is currently trading near its 52-week high $0.89 and $2.66. With a market capitalization of about $114.24 million, Repare Therapeutics Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 1.18 million shares, in line with its 52-week average. Headquartered in Montreal, QC, Repare Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steve Forte, the company employs approximately 129 people and listed since June 19, 2020. Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 2.62%, SMA50 13.82%, SMA200 51.82%). The stock’s 14-day RSI is 73.22 (overbought), while the ATR of 0.05 points to moderate volatility. The stock remains hovering near 52-week lows, trading -0.38% below its high and over 197.75% above its low.

Valuation Metrics

Repare Therapeutics Inc. trades at a P/E ratio of -1.58, slightly below the S&P 500 average, with a price-to-sales ratio of 9.62 and a price-to-book ratio of 0.99 suggesting the stock is closer to book value. The P/FCF stands at -1.63, also above market averages.

Dividend & Fair Value

Repare Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.95. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Repare Therapeutics Inc. generated EPS of -$1.69 over the past year. Five-year average earnings growth is -21.89%. The latest quarter delivered EPS of -$0.67. The next quarter is forecast at $nan. Next year's EPS is expected at -$76.89. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 13.21% upside. The low target suggests 13.21% downside. The mean target is $3.00. This offers 13.21% upside. Repare Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by 131.03%. The prior quarter beat by -121.62%. Over the last six quarters, Apple has recorded several small beats. These include -2.35% in November 07, 2024.

Shareholding & Insider Activity

Repare Therapeutics Inc. has 42.96 million shares outstanding. The public float is 22.72 million shares, elevated short interest at 2.35% of float. This equals 685.46 thousand shares. The short ratio is 1.07 days. Institutional investors hold 65.75% of the float. Insiders own 1.25%. LAMPERT MARK N holds 4.44 million shares, GADICKE ANSBERT has 3.88 million shares and Foley Todd has 2.24 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Repare Therapeutics generated $51.13M in revenue, or $1.21 per share. Gross margin was 96.18%, operating margin -224.43%, and net profit margin -183.44%. Returns are negative, with ROA at -36.94% and ROE at -44.23%.
On valuation metrics, Repare Therapeutics trades at a P/E of -1.58, P/S of 9.62 and P/B of 0.99. The current ratio is 10.71 and quick ratio is 10.71. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -84.94 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -205.11.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Repare Therapeutics posted revenue of $51.13M, down slightly from $131.83M in the prior quarter. Gross profit was $49.18M (margin 96.18%). Operating income was - $114.76M (margin -224.4%). Net income was- $93.80M (EPS - $2.23).
The company ended the quarter with $223.63M in cash and short-term investments, a total debt of $3.41M, and net debt of - $107.86M. Total assets were $253.90M, with equity of $212.08M. Financials further reflected weakness, with operating cash flow of - $127.16M, free cash flow of - $129.10M, and capital expenditures of - $1.94M.

Price Forecast & Outlook

Our AI price prediction model suggests that Repare Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.02%, with price expected at $2.73 by February 10, 2026, within a range of $2.62 to $2.84 3-Month Outlook: Projected rise of 286.42%, reaching $10.24 by April 27, 2026, with a range of $10.13 to $10.52. 1-Year Outlook: Projected gain of 317.36%, with price at $11.06 by January 27, 2027, within a range of $0.00 to $16.69.

Key Takeaways

Repare Therapeutics Inc. (NASDAQ:RPTX) shares are flat -0.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Repare Therapeutics Inc. trading at a premium to the broader market with a P/E of -1.58. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.45, suggesting 822.64% upside. Our AI forecast model points to short-term strength (3.02% over two weeks), a medium-term rise (286.42% over three months), and a longer-term gain (317.36% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Repare Therapeutics Inc. (RPTX) stock price?

Repare Therapeutics Inc. (NASDAQ: RPTX) stock price is $2.65 in the last trading session. During the trading session, RPTX stock reached the peak price of $2.65 while $2.65 was the lowest point it dropped to. The percentage change in RPTX stock occurred in the recent session was 0% while the dollar amount for the price change in RPTX stock was $0.00.

RPTX's industry and sector of operation?

The NASDAQ listed RPTX is part of Biotechnology industry that operates in the broader Healthcare sector. Repare Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RPTX?

Dr. Frank Sicheri Ph.D.
Co-Founder
Dr. Daniel Durocher Ph.D.
Co-Founder
Dr. Michael Zinda Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Cameron Black
Executive Vice President of Discovery
Mr. Philip Herman
Executive Vice President, Chief Commercial & Portfolio Devel. Officer
Dr. Kim A. Seth Ph.D.
Executive Vice President & Chief Bus. Officer
Mr. Steve Forte
Executive Vice President & Chief Financial Officer
Dr. Agnel Sfeir Ph.D.
Co-Founder
Mr. Daniel Belanger
Executive Vice President of Human Resource
Dr. Maria Koehler M.D., Ph.D.
Executive Vice President & Chief Medical Officer
Mr. Lloyd Mitchell Segal
Pres, Chief Executive Officer & Director

How RPTX did perform over past 52-week?

RPTX's closing price is 197.75% higher than its 52-week low of $0.89 where as its distance from 52-week high of $2.66 is -0.38%.

How many employees does RPTX have?

Number of RPTX employees currently stands at 129.

Link for RPTX official website?

Official Website of RPTX is: https://www.reparerx.com

How do I contact RPTX?

RPTX could be contacted at phone 857 412 7018 and can also be accessed through its website. RPTX operates from 7210 Frederick-Banting, Montreal, QC H4S 2A1, Canada.

How many shares of RPTX are traded daily?

RPTX stock volume for the day was 1.17M shares. The average number of RPTX shares traded daily for last 3 months was 1.18M.

What is the market cap of RPTX currently?

The market value of RPTX currently stands at $114.24M with its latest stock price at $2.65 and 43.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	129
Beta	0.96
Sales or Revenue	$51.13M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RPTX Company Profile and Key Details

Repare Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics